Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease

References

• LainscakMClelandJGLenzenMJFollathFKomajdaMSwedbergKInternational variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure SurveyEur J Heart Fail2007929229917023204
   PubMed Web of Science ®Google Scholar
• HawkinsNMPetrieMCJhundPSChalmersGWDunnFGMcMurrayJJHeart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiologyEur J Heart Fail20091113013919168510
   PubMed Web of Science ®Google Scholar
• SinDDMcAlisterFAThe effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failureAm J Med200211365065612505115
   PubMed Web of Science ®Google Scholar
• KomajdaMFollathFSwedbergKThe EuroHeart Failure Survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 2: treatmentEur Heart J20032446447412633547
   PubMed Web of Science ®Google Scholar
• HawkinsNMPetrieMCMacdonaldMRHeart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonistsJ Am Coll Cardiol2011572127213821596228
   PubMed Web of Science ®Google Scholar
• DicksteinKCohen-SolalAFilippatosGESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)Eur Heart J2008292388244218799522
   PubMed Web of Science ®Google Scholar
• Al-MohammadAMantJThe diagnosis and management of chronic heart failure: review following the publication of the NICE guidelinesHeart20119741141621296784
   PubMed Web of Science ®Google Scholar
• GottliebSSMcCarterRJVogelRAEffect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarctionN Engl J Med19983394894979709041
   PubMed Web of Science ®Google Scholar
• GalatiusSGustafssonFAtarDHildebrandtPRTolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure – a randomized comparisonCardiology200410216016515334027
   PubMed Web of Science ®Google Scholar
• JabbourAMacdonaldPSKeoghAMDifferences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trialJ Am Coll Cardiol2010551780178720413026
   PubMed Web of Science ®Google Scholar
• LainscakMPodbregarMKovacicDRozmanJvon HaehlingSDifferences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trialRespir Med2011105suppl 1S44S4922015086
   PubMed Web of Science ®Google Scholar
• NiYShiGWanHUse of cardioselective beta-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trialsJ Int Med Res2012402051206523321161
   PubMed Web of Science ®Google Scholar
• LothDWBrusselleGGLahousseLHofmanALeufkensHGStrickerBHBeta-Adrenoceptor blockers and pulmonary function in the general population: the Rotterdam StudyBr J Clin Pharmacol20147719020023772842
   PubMed Web of Science ®Google Scholar
• BristowMRGilbertEMAbrahamWTCarvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA InvestigatorsCirculation199694280728168941106
   PubMed Web of Science ®Google Scholar
• PackerMBristowMRCohnJNThe effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study GroupN Engl J Med1996334134913558614419
   PubMed Web of Science ®Google Scholar
• PackerMFowlerMBRoeckerEBCarvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study GroupEffect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) studyCirculation20021062194219912390947
   PubMed Web of Science ®Google Scholar
• Poole-WilsonPASwedbergKClelandJGCarvedilol Or Metoprolol European Trial InvestigatorsComparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trialLancet200336271312853193
   PubMed Web of Science ®Google Scholar
• HoriMSasayamaSKitabatakeAMUCHA InvestigatorsLow-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trialAm Heart J200414732433014760332
   PubMed Web of Science ®Google Scholar
• A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and CommitteesCirculation199490176517737923660
   PubMed Web of Science ®Google Scholar
• The Cardiac Insufficiency Bisoprolol Study II(CIBIS-II): a randomised trialLancet199935391310023943
   PubMed Web of Science ®Google Scholar
• WillenheimerRvan VeldhuisenDJSilkeBCIBIS III InvestigatorsEffect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) IIICirculation20051122426243516143696
   PubMed Web of Science ®Google Scholar
• MentzRJWojdylaDFiuzatMChiswellKFonarowGCO’ConnorCMAssociation of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF)Am J Cardiol201311158258723200803
   PubMed Web of Science ®Google Scholar
• McKeePACastelliWPMcNamaraPMThe natural history of congestive heart failure: the Framingham studyN Engl J Med1971285144114465122894
   PubMed Web of Science ®Google Scholar
• RabeKFHurdSAnzuetoAGlobal Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med200717653255517507545
   PubMed Web of Science ®Google Scholar
• LeveyASBoschJPLewisJBGreeneTRogersNRothDA more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study GroupAnn Intern Med199913046147010075613
   PubMed Web of Science ®Google Scholar
• ManninoDMThornDSwensenAHolguinFPrevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPDEur Respir J20083296296918579551
   PubMed Web of Science ®Google Scholar
• ZielinskiJMacNeeWWedzichaJCauses of death in patients with COPD and chronic respiratory failureMonaldi Arch Chest Dis19975243479151520
   PubMedGoogle Scholar
• AnthonisenNRConnettJEMurrayRPSmoking and lung function of Lung Health Study participants after 11 yearsAm J Respir Crit Care Med200216667567912204864
   PubMed Web of Science ®Google Scholar
• HolguinFFolchEReddSCManninoDMComorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001Chest20051282005201116236848
   PubMed Web of Science ®Google Scholar
• DransfieldMTRoweSMJohnsonJEBaileyWCGeraldLBUse of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPDThorax20086330130517951276
   PubMed Web of Science ®Google Scholar
• ShortPMLipworthSIElderDHEffect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort studyBMJ2011342d254921558357
   PubMed Web of Science ®Google Scholar
• StefanMSRothbergMBPriyaAPekowPSAuDHLindenauerPKAssociation between beta-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertensionThorax20126797798422941975
   PubMed Web of Science ®Google Scholar
• AlbouainiKAndronMAlahmarABeta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditionsInt J Chron Obstruct Pulmon Dis2007253554018268926
   PubMedGoogle Scholar
• RuttenFHZuithoffNPHakEGrobbeeDEHoesAWBeta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary diseaseArch Intern Med201017088088720498416
   PubMed Web of Science ®Google Scholar
• FarlandMZPetersCJWilliamsJDBielakKMHeidelRERaySMBeta-Blocker use and incidence of chronic obstructive pulmonary disease exacerbationsAnn Pharmacother20134765165623585645
   PubMed Web of Science ®Google Scholar
• ZengLHHuYXLiuLZhangMCuiHImpact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary diseaseClin Interv Aging201381157116524072964
   PubMed Web of Science ®Google Scholar
• Puente-MaestuLCalleMOrtega-GonzálezAGEMEPOC GroupMulticentric study on the beta-blocker use and relation with exacerbations in COPDRespir Med201410873774424635914
   PubMed Web of Science ®Google Scholar
• DuQSunYDingNLuLChenYBeta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studiesPLoS One20149e11304825427000
   PubMed Web of Science ®Google Scholar
• EtminanMJafariSCarletonBFitzGeraldJMBeta-blocker use and COPD mortality: a systematic review and meta-analysisBMC Pulm Med2012124822947076
   PubMed Web of Science ®Google Scholar
• QuintJKHerrettEBhaskaranKEffect of beta blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare recordsBMJ2013347f665024270505
   PubMed Web of Science ®Google Scholar
• LechatPHulotJSEscolanoSHeart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II TrialCirculation20011031428143311245648
   PubMed Web of Science ®Google Scholar
• DorowPBethgeHTonnesmannUEffects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectorisEur J Clin Pharmacol1986311431472879733
   PubMed Web of Science ®Google Scholar
• Macquin-MavierIRoudot-ThoravalFClericiCGeorgeCHarfAComparative effects of bisoprolol and acebutolol in smokers with airway obstructionBr J Clin Pharmacol1988262792842902873
   PubMed Web of Science ®Google Scholar
• SalpeterSOrmistonTSalpeterECardioselective beta-blockers for chronic obstructive pulmonary diseaseCochrane Database Syst Rev2005CD00356616235327
   PubMed Web of Science ®Google Scholar
• NozawaTTaguchiMTaharaKInfluence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprololJ Cardiovasc Pharmacol20054671372016220080
   PubMed Web of Science ®Google Scholar
• TaguchiMNozawaTIgawaAPharmacokinetic variability of routinely administered bisoprolol in middle-aged and elderly Japanese patientsBiol Pharm Bull20052887688115863897
   PubMed Web of Science ®Google Scholar
• HondaMOguraYToyodaWMultiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteersBiol Pharm Bull20062977277816595916
   PubMed Web of Science ®Google Scholar
• NulDZambranoCDiazAGrupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en ArgentinaImpact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registryCardiovasc Drugs Ther20051912513416025231
   PubMed Web of Science ®Google Scholar
• TaniguchiTOhtaniTMizoteISwitching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotensionJ Cardiol20136141742223548374
   PubMed Web of Science ®Google Scholar
• SimonTMary-KrauseMFunck-BrentanoCBisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II)Eur Heart J20032455255912643888
   PubMed Web of Science ®Google Scholar
• NishiyamaKTsutamotoTYamajiMDose-dependent prognostic effect of carvedilol in patients with chronic heart failure – special reference to transcardiac [corrected] gradient of norepinephrineCirc J2009732270227519838002
   PubMed Web of Science ®Google Scholar
• MateraMGMartuscelliECazzolaMPharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failurePulm Pharmacol Ther2010231819833222
   PubMed Web of Science ®Google Scholar
• KonishiMHaraguchiGKimuraSComparative effects of carvedilol vs bisoprolol for severe congestive heart failureCirc J2010741127113420354334
   PubMed Web of Science ®Google Scholar
• DüngenHDApostolovicSInkrotSCIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart FailureTitration to target dose of bisoprolol vs carvedilol in elderly patients with heart failure: the CIBIS-ELD trialEur J Heart Fail20111367068021429992
   PubMed Web of Science ®Google Scholar
• Di LenardaARemmeWJCharlesworthACOMET InvestorsExchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial)Eur J Heart Fail2005764064915921806
   PubMed Web of Science ®Google Scholar